Level 1 LDI: Selecting an appropriate benchmark
AH Meder - The Journal of Investing, 2012 - pm-research.com
We define level 1–LDI implementation as implementation done without the use of derivatives
and an explicit liability benchmark. For level 1–LDI plan sponsors, we find that their biggest …
and an explicit liability benchmark. For level 1–LDI plan sponsors, we find that their biggest …
[PDF][PDF] Risks and Rewards Newsletter, August 2006, Issue No. 48
AH Meder, NA Boezio, MDJ Evans - 2006 - soa.org
… by Aaron Meder … by Aaron Meder … h. Done based on both a risk neutral account
value projection to predict customer behavior and using a real world shadow account. …
value projection to predict customer behavior and using a real world shadow account. …
Comparison and consensus guidelines for delineation of clinical target volume for CT-and MR-based brachytherapy in locally advanced cervical cancer
AN Viswanathan, B Erickson, DK Gaffney… - International Journal of …, 2014 - Elsevier
Objective To create and compare consensus clinical target volume (CTV) contours for
computed tomography (CT) and 3-Tesla (3-T) magnetic resonance (MR) image-based cervical-…
computed tomography (CT) and 3-Tesla (3-T) magnetic resonance (MR) image-based cervical-…
Managing Pension Liability Credit Risk: Maintaining a Total Portfolio Perspective
A Meder - Journal of Portfolio Management, 2009 - search.proquest.com
… Meder recommends that, from a long-term policy perspective, plan sponsors should generally
avoid credit risk in the liability hedge. From a tactical perspective, however, adding credit …
avoid credit risk in the liability hedge. From a tactical perspective, however, adding credit …
American College of Radiology appropriateness criteria on multiple brain metastases
GMM Videtic, LE Gaspar, AM Aref… - International journal of …, 2009 - redjournal.org
BACKGROUND As many as 170,000 cancer patients will develop brain metastases each
year (1). Brain metastases represent the most common neurologic manifestation of cancer, …
year (1). Brain metastases represent the most common neurologic manifestation of cancer, …
ACR appropriateness criteria® on advanced cervical cancer expert panel on radiation oncology—Gynecology
DK Gaffney, BA Erickson-Wittmann, A Jhingran… - International Journal of …, 2011 - Elsevier
The management of advanced cancer of the cervix has continued to evolve. The disease
remains a severe worldwide public health problem. It is the second-leading cause of cancer …
remains a severe worldwide public health problem. It is the second-leading cause of cancer …
[PDF][PDF] Investment Section, Issue No. 48, August 2006 Risks and Rewards newsletter
A Meder, S Whelan, N Holland, N Boezio - 2006 - Citeseer
… by Aaron Meder … by Aaron Meder … h. Done based on both a risk neutral account
value projection to predict customer behavior and using a real world shadow account. …
value projection to predict customer behavior and using a real world shadow account. …
Atlas of the clinical genetics of human dilated cardiomyopathy
Aim Numerous genes are known to cause dilated cardiomyopathy (DCM). However, until
now technological limitations have hindered elucidation of the contribution of all clinically …
now technological limitations have hindered elucidation of the contribution of all clinically …
Phase coexistence and connectivity in the apical membrane of polarized epithelial cells
Although it is well described in model membranes, little is known about phase separation in
biological membranes. Here, we provide evidence for a coexistence of at least two different …
biological membranes. Here, we provide evidence for a coexistence of at least two different …
Endovascular treatment of intracranial unruptured aneurysms: a systematic review of the literature on safety with emphasis on subgroup analyses
Purpose To report subgroup analyses of an updated systematic review on endovascular
treatment of intracranial unruptured aneurysms (UAs); to compare types of embolic agents, …
treatment of intracranial unruptured aneurysms (UAs); to compare types of embolic agents, …